

## SUPPLEMENTARY DATA

Table 1 of the supplementary data

Baseline and Procedural Characteristics and In-hospital Outcomes According to Elevated Galectin-3

|                                   | Elevated Galectin-3<br>(≥ 8.71 ng/mL) |                     | <i>P</i> |
|-----------------------------------|---------------------------------------|---------------------|----------|
|                                   | No<br>(n = 299)                       | Yes<br>(n = 140)    |          |
| Age, y                            | 81.0 [77.0-84.5]                      | 81.0 [77.0-85.0]    | .928     |
| Female sex                        | 133 (44.5)                            | 66 (47.1)           | .675     |
| BMI, kg/m <sup>2</sup>            | 25.7 [23.6-28.7]                      | 26.2 [23.3-30.8]    | .290     |
| Logistic EuroSCORE I, %           | 13.9 [7.9-19.5]                       | 14.7 [9.5-24.6]     | .016     |
| NYHA class III/IV                 | 174 (58.2)                            | 100 (71.4)          | .010     |
| Hypertension                      | 270 (90.3)                            | 128 (91.4)          | .840     |
| Hypercholesterolemia              | 232 (77.6)                            | 116 (82.9)          | .253     |
| Diabetes mellitus                 | 70 (23.4)                             | 45 (32.1)           | .068     |
| Coronary artery disease           | 220 (73.6)                            | 104 (74.3)          | .968     |
| Previous myocardial infarction    | 26 (8.7)                              | 17 (12.1)           | .337     |
| Previous PCI                      | 131 (43.8)                            | 67 (47.9)           | .490     |
| Previous CABG                     | 35 (11.7)                             | 14 (10.0)           | .714     |
| Previous stroke                   | 28 (9.4)                              | 24 (17.1)           | .028     |
| Previous cancer                   | 59 (19.7)                             | 32 (22.9)           | .531     |
| Previous pacemaker                | 35 (11.7)                             | 20 (14.3)           | .544     |
| Peripheral artery disease         | 40 (13.4)                             | 19 (13.6)           | 1.000    |
| COPD                              | 39 (13.0)                             | 32 (22.9)           | .014     |
| Atrial fibrillation               | 117 (39.1)                            | 65 (46.4)           | .179     |
| Hemoglobin, g/dL                  | 12.8 [11.6-13.9]                      | 12.6 [11.1-13.7]    | .168     |
| Creatinine clearance, mL/min      | 56.0 [43.0-68.5]                      | 49.0 [35.8-62.2]    | .001     |
| CRP, mg/L                         | 1.9 [1.0-5.2]                         | 3.0 [1.1-7.8]       | .015     |
| NTproBNP, ng/L                    | 1500 [602-3575]                       | 2520 [769-4770]     | .020     |
| CA125, U/mL                       | 18.1 [10.8-38.0]                      | 21.7 [13.0-40.8]    | .066     |
| Galectin-3, ng/mL                 | 6.0 [4.6-7.3]                         | 10.4 [9.3-14.5]     | < .001   |
| LV ejection fraction ≤ 35%        | 23 (7.7)                              | 18 (12.9)           | .119     |
| Mitral regurgitation grade III/IV | 11 (3.7)                              | 12 (8.6)            | .056     |
| PAP > 60 mmHg                     | 32 (10.7)                             | 23 (16.4)           | .125     |
| Mean transaortic gradient, mmHg   | 45.0 [37.5-53.0]                      | 41.0 [30.0-51.0]    | .003     |
| Device success                    | 261 (87.3)                            | 126 (90.0)          | .509     |
| Procedural success                | 291 (97.3)                            | 139 (99.3)          | .283     |
| Procedural time, min              | 49.0 [40.5-57.0]                      | 49.5 [40.0-61.0]    | .399     |
| Fluoroscopy time, min             | 11.4 [8.5-14.2]                       | 11.6 [9.2-16.2]     | .068     |
| Contrast, mL                      | 110.0 [90.0-140.0]                    | 120.0 [100.0-140.0] | .109     |
| Major vascular complication       | 43 (14.4)                             | 21 (15.0)           | .979     |
| Life-threatening bleeding         | 9 (3.0)                               | 8 (5.7)             | .270     |
| Blood transfusion, ≥ 2 units      | 36 (12.0)                             | 17 (12.1)           | 1.000    |
| Major stroke                      | 1 (0.3)                               | 4 (2.9)             | .038     |
| Renal failure                     | 2 (0.7)                               | 8 (5.7)             | .002     |
| New pacemaker implantation        | 17 (5.7)                              | 8 (5.7)             | 1.000    |
| Days in hospital                  | 4.0 [4.0-6.0]                         | 5.0 [4.0-6.0]       | < .001   |
| Days in intensive care unit       | 1.0 [1.0-1.0]                         | 1.0 [1.0-2.0]       | < .001   |

BMI, body mass index; CA125, carbohydrate antigen 125; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; NTproBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PCI, percutaneous coronary intervention.

The data are expressed as No. (%) or median [interquartile range].

Table 2 of the supplementary data

Incremental Prognostic Value of Gal3+ to Baseline Variables and CA125 and Within CA125 Stratae

|                            | AUC         |                                 | Reclassification    |                  |
|----------------------------|-------------|---------------------------------|---------------------|------------------|
|                            | Base model* | Base model <sup>a</sup> + Gal3+ | NRI [95%CI]         | IDI [95%CI]      |
| All (n = 439) <sup>b</sup> | .745        | .748                            | 38.4 (-17.6, 65.4)  | 1.0 (-0.3, 4.1)  |
| CA125+ (n = 228)           | .687        | .712                            | 49.2 (5.1, 77.8)    | 2.5 (-0.3, 8.6)  |
| CA125- (n = 211)           | .438        | .411                            | -84.2 (-76.1, 76.7) | -0.4 (-1.6, 4.6) |

95%CI, 95% confidence interval; AUC, area under the curve; CA125, carbohydrate antigen 125; EuroSCORE, European System for Cardiac Operative Risk Evaluation; NRI, net reclassification improvement, IDI, integrated discrimination improvement

<sup>a</sup>Including age, logistic EuroSCORE I, previous myocardial infarction, previous malignancy, atrial fibrillation, mitral regurgitation grade III/IV, pulmonary hypertension (PAP > 60 mmHg), hemoglobin (g/dL), creatinine clearance (mL/min), N-terminal pro-B-type natriuretic peptide (ng/L), Mean transaortic gradient (mmHg).

<sup>b</sup>Base model + CA125+

Figure 1 of the supplementary data. Kaplan-Meier event rate according to CA125. Kaplan-Meier estimates for the primary endpoint with differences tested using the log rank test. +, elevated, -, not elevated.

